Creating cell lines with future manufacturability, cost of goods and speed in mind is of critical importance. How can time to the clinic be reduced and yet a drug candidate be equipped with a robust CMC-package from day one?

Join Jennifer Peuchot, Group Leader in the Cell Culture Development team at Lonza Biologics to learn how you can chart an optimal path from gene to the clinic by tailoring your cell line development program to match your molecule type, timelines, yield requirements and risk priorities.

Backed by case studies, we will discuss

  • How to effectively combine host cell line, vector and stringency of selection to develop high producing cell lines suited to fit a commercially relevant platform process.
  • How to quickly and reliably express new molecular formats and achieve appropriate product characteristic profile
  • How to accelerate your path to tox drug product and to the clinic while minimizing risk

Featured Speaker

Jennifer Peuchot

Group Leader in the Cell Culture Development team
Lonza Biologics

After her Master's degree in Cell Biology, she rapidly joined Lonza where she has been developing cell lines for biotherapeutics manufacturing. With over ten years of experience in cell culture, cell line construction and upstream process transfer, she has been leading numerous customer programmes, including bespoke cell line development and upstream process optimisation for complex proteins.

Date:  Thursday, September 23, 2021
Time:  11am ET / 8am PT
Duration:  1 Hour

Register now for this webinar